Icade's Disciplined Pivot: Eqho, Healthcare Exits, and the Low-Point Play
H1 2026 shows a company executing its ReShapE plan with precision, balancing disposals with strategic acquisitions while confirming trough cash flows.
ICAD.PA · Earnings Call · 2026-07-22
H1 2026: Execution Over Celebration
Icade's first half of 2026 delivered on the promises of its ReShapE plan, but the story is less about headline numbers than about the discipline with which the company is repositioning itself. The sale of the Marignan building on the Champs-Élysées for €402 million and the agreement to dispose of its Portuguese healthcare portfolio are steps that crystallize value without chasing liquidity. As CEO Nicolas Joly noted, “we completed the sale of the Marignan building on the Champs-Élysées for EUR 402 million.” — Nicolas Joly, CEO · 2026-07-22 That disposal, achieved at a price more than 20% above the December 2024 NAV, exemplifies the company's insistence on selling only when conditions are attractive. The most operationally significant move was the full acquisition of the Eqho tower in La Défense. By buying out the 49% minority stake, Icade regained full ownership of a landmark asset that is now fully let. The yield on the acquisition, above 8%, and the accretive impact on cash flow make this a textbook example of capital discipline. In the words of the CEO during Q&A, “we were able to sell this portfolio, which is roughly EUR 200 million on a quite narrow market at satisfying condition on the NAV” — Nicolas Joly, CEO · 2026-07-22 — though that remark was about healthcare, it reflects a broader philosophy of waiting for the right window. The Eqho deal is a deliberate redeployment of proceeds from disposals into higher-return opportunities, a theme that also includes data centers and student housing.Healthcare: Patient Exit, Real Value
The Portuguese healthcare portfolio, with an economic stake of €75 million, was sold at a valuation in line with December 2025 NAV. This is not a fire sale; it is a carefully timed exit. The company's willingness to wait for the right window is a recurring theme from prior quarters. In February, Joly had said: “we are confident on the low points” — Nicolas Joly, Chief Executive Officer (CEO) · 2026-02-18 — a confidence now being tested. The continued execution of the exit plan, with around €900 million of healthcare exposure still to be disposed of by the end of the plan, is on track. The proceeds are being redeployed into areas where Icade sees structural growth. The strategic partnerships announced in July — one for student accommodation with Caisse des Dépôts and another, Evolution Habitat, to convert vacant offices into residential — are capital-light ways to tap into demand without overextending the balance sheet. “we confirm the guidance 2026 and the fact that strategic cash flow should mark a low point in 2026.” — Nicolas Joly, CEO · 2026-07-22 This confirmation comes amidst a still-uncertain market, but the company's operational resilience is visible in the occupancy rate, which reached 85.9% with office occupancy close to 90%. The renewal of the Grands Axes lease with AXA for 58,000 sq m on a nine-year firm term is a major de-risking event, demonstrating the strength of the asset and long-term tenant relationships.2026: The Confirmed Low Point
The full-year guidance of group net current cash flow between €2.90 and €3.10 per share was reaffirmed, with the company emphasizing that 2026 should be the trough for strategic cash flows. The drivers are well understood: finance costs are gradually normalizing, rental income still faces negative reversion and low indexation, but the development business is improving and cost reductions are starting to show. LTV improved slightly to 39%, and liquidity remains robust at €2.5 billion.We confirm the guidance 2026 and the fact that strategic cash flow should mark a low point in 2026.